Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 2185 • ACR Convergence 2023
35 Years Follow-up of Primary Sjögren’s Disease: A Single Center Study
Lorena Montano-Tapia¹, Resit Yildrim², Ana Mafalda Abrantes³ and David Isenberg⁴, ¹Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ²Eskişehir Osmangazi University I, Eskişehir, Turkey, ³Centro Hospitalar Universitario Lisboa Norte, Lisbon, Portugal, ⁴University College London, London, United Kingdom
Background/Purpose: Primary Sjögren’s syndrome (pSS) is an autoimmune rheumatic disease characterized by lymphocytic infiltration of exocrine glands. Its clinical manifestations are heterogeneous. Currently, the evidence…
Abstract Number: 0277 • ACR Convergence 2023
Anti-carbamylated Antibodies in Autoimmunity – Focus on Their Diagnostic and Prognostic Value: A Systematic Review and Meta-analysis
Julie Sarrand, Dorian Parisis, Muhammad Soyfoo and Paschalis Sidiras, Erasmus Hospital, Brussels, Belgium
Background/Purpose: This is the first systematic review and meta-analysis to examine the prevalence, the diagnostic and the prognostic value of anti-carbamylated protein (CarP) antibodies in…
Abstract Number: 1369 • ACR Convergence 2023
Treatment Patterns and Drivers of Biologic Prescriptions in Patients with Primary Sjögren’s Disease: Results from a Multinational, Real-World Survey
Sara McCoy¹, Alan Baer², Ann Xi³, Giorgio Castellano⁴, Victoria Barton⁴, Anthony Amatucci⁵, Ilias Alevizos⁶ and Haridarshan Patel⁷, ¹University of Wisconsin School of Medicine and Public Health, Middleton, WI, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Horizon Therapeutics, Indianapolis, IN, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Horizon Therapeutics, Cambridge, MA, ⁶Horizon Therapeutics, Rockville, MD, ⁷Horizon Therapeutics, Deerfield, IL
Background/Purpose: Currently, no systemic therapies have been approved for Sjögren's disease (SjD) due to limited evidence regarding efficacy. However, biologics are often used in patients…
Abstract Number: 1634 • ACR Convergence 2023
Iscalimab (CFZ533) in Patients with Sjögren’s Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study
Benjamin A Fisher¹, Xavier Mariette², Athena S Papas³, Thomas Grader-Beck⁴, Hendrika Bootsma⁵, Wan-Fai Ng⁶, Paul Van Daele⁷, Stephanie Finzel⁸, Sergio Elgueta⁹, Josef Hermann¹⁰, Sara McCoy¹¹, Arthur Bookman¹², Monika Sopala¹³, Wen-Lin Luo¹⁴, Cornelia Scheurer¹³ and Wolfgang Hueber¹³, ¹University of Birmingham, Birmingham, United Kingdom, ²Université Paris-Saclay, Le Kremlin-Bicêtre, France, ³Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA, ⁴Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁵Department of Rheumatology, University Medical Centre Groningen, Groningen, Netherlands, ⁶NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁷Department of internal medicine, Erasmus MC, Rotterdam, Netherlands, ⁸Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, ⁹Clinical Research Chile SpA, Biomedical Research Centre, Valdivia, Chile, ¹⁰Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz, Graz, Austria, ¹¹University of Wisconsin School of Medicine and Public Health, Middleton, WI, ¹²Toronto Western Hospital, Toronto, ON, Canada, ¹³Novartis Pharma AG, Basel, Switzerland, ¹⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Sjögren's disease (SjD) is an autoimmune disease affecting secretory glands and other organs with no approved systemic treatments. Iscalimab (CFZ533) is a mAb directed…
Abstract Number: 2186 • ACR Convergence 2023
Neurological Complications in Sjögren’s: Occurrence & Impact on Patient Quality of Life
Matt Makara, Janet Church and Katherine Hammitt, Sjögren’s Foundation, Reston, VA
Background/Purpose: Sjögren's is a serious and systemic autoimmune disease that affects the entire body, including the nervous system. This study aimed to better understand the…
Abstract Number: 0343 • ACR Convergence 2023
Sjögren’s Disease Patient Experiences with Dry Mouth and Content Validity of the Xerostomia Inventory
Denise Kruzikas¹, Ann Eldred², Shelly Kafka³, Janet Church⁴, Katherine Hammitt⁴, Patricia Koochaki⁵, Christina O'Donnell⁶ and William Thomson⁷, ¹AbbVie, Inc., North Chicago, IL, ²AbbVie, Inc., Lake Bluff, IL, ³AbbVie, Inc., Norristown, PA, ⁴Sjögren’s Foundation, Reston, VA, ⁵ICON Clinical Research LLC, Raleigh, NC, ⁶ICON plc, Raleigh, NC, ⁷Department of Oral Sciences, Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin, New Zealand
Background/Purpose: Xerostomia (dry mouth) is one of the most prevalent symptoms experienced by patients with Sjögren’s Disease (SJD). The Xerostomia Inventory (XI) is a 11-item…
Abstract Number: 1370 • ACR Convergence 2023
Synthetic Glabridin Derivatives Improves Sjogren’s Syndrome by Inducing Salivary Secretion and Salivary Gland Regeneration
Eui-Jong Kwon¹, Jin-Sil Park², Ha Yeon Jeong³, Hye Yeon Kang⁴, JeongWon Choi³, Mi-La Cho³ and Sung-Hwan Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea Seoul St. Mary's Hospital, Seocho-gu, South Korea, ²The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, ³Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Sjogren’s syndrome (SS) is a systemic autoimmune disease characterized by infiltration of lymphocytes into the exocrine gland resulting in progressive lacrimal and salivary estruction…
Abstract Number: 1635 • ACR Convergence 2023
Deep Learning Accurately Predicts Focus Score and Diagnosis of Primary Sjögren Syndrome Using Labial Salivary Gland Biopsies
Louis Basseto¹, Julien Duquesne¹, Michael Barnes², Elena Pontarini², Amaya Gallagher-Syed², Michele Bombardieri², Benjamin A Fisher³, Saba Nayar³, Clovis Adam⁴, Thierry Lazure⁴, Xavier Mariette⁵, Samuel Bitoun⁶ and Vincent Bouget¹, ¹Scienta Lab, Paris, France, ²Queen Mary University of London, London, United Kingdom, ³University of Birmingham, Birmingham, United Kingdom, ⁴Université Paris-Saclay, Paris, France, ⁵Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁶CHU Bicêtre APHP, Le Kremlin-Bicêtre, France
Background/Purpose: Primary Sjögren Syndrome (pSS) diagnosis relies on the weighted sum of three EULAR/ACR 2016 criteria: i) quantification of lymphocyte infiltration in labial salivary gland…
Abstract Number: 2187 • ACR Convergence 2023
Association Between Illness Perception, Anxiety and Depression State, Disease Activity and Glucocorticoid Therapy in Patients with Sjӧgren’s Syndrome
Chiara Baldini¹, Elena Elefante², Inmaculada Conception Navarro Garcia², Francesco Ferro³, Gaetano La Rocca⁴, Giovanni Fulvio¹, Silvia Fonzetti⁵, Michele Moretti⁶ and Marta Mosca², ¹University of Pisa, Pisa, Italy, ²Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁴University of Pisa, Rheumatology Unit, Pisa, Italy, ⁵AOUP, Pisa, Italy, ⁶Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Background/Purpose: Sjӧgren's syndrome (SS) may affect several aspects of patients' daily lives, leading to impairment of quality of life and patient functioning. Aims of this…
Abstract Number: 0464 • ACR Convergence 2023
Adverse Pregnancy Outcomes in Sjogren’s Disease Compared to Controls: An Interdisciplinary Approach with Maternal Fetal Medicine
Lauren Tesoriero¹, Jennifer Kidd¹, Julie Piccione¹, Izmirly peter², Meredith Akerman¹, Steven Carsons¹, Patricia Rekawek¹ and Julie Nusbaum¹, ¹NYU Long Island School of Medicine, Mineola, NY, ²NYU, New York, NY
Background/Purpose: Outside of the known association of Ro antibody with congenital heart block (CHB), little is known about adverse maternal outcomes, and even less about…
Abstract Number: 1371 • ACR Convergence 2023
Are Ultrasound Salivary Parenchymal Abnormalities More Severe in Primary Sjögren Patients with a Higher Disease Duration ? A Cross-sectional International Study
Alice TISON¹, sandrine jousse joulin², Maëlys Consigny³, Philipp Moog⁴, Benedikt Hofauer⁵, Eric Hachulla⁶, Christophe Lamotte⁷, JACQUES MOREL⁸, Gael Mouterde⁹, Vera Milic¹⁰, Hendrika Bootsma¹¹, Alja Stel¹², Benjamin A Fisher¹³, Mark Maybury¹⁴, Alan Baer¹⁵, Dana Direnzo¹⁶, Hae-Rim Kim¹⁷, Hong Ki Min¹⁸, Shin-Seok Lee¹⁹, Sung-Eun Choi¹⁹, Guillermo CARVAJAL ALEGRIA²⁰, Sylvie Boisramé²¹, Dewi Guellec²², Divi Cornec²³, Malin Jonsson²⁴, Daniel Hammenfors²⁵, Alain SARAUX²⁶ and Valerie Devauchelle²⁷, ¹CHU de la Cavale Blanche, Brest, France, ²Rheumatology, CHU Brest, Brest, France, ³Biostatistics, CHU Brest, Brest, France, ⁴Rheumatology, CHU Munich, Munich, Germany, ⁵Otolaryngology, CHU Munich, Munich, Germany, ⁶University of Lille, Lille, France, ⁷Internal Medicine and Clinical Immunology, CHU Lille, Lille, France, ⁸Protocole thérapeutique immuno-rhumatologie, Montpellier, France, ⁹CHU Lapeyronie, Montpellier, France, ¹⁰Rheumatology, University of Belgrade, Medical School, Belgrade, Serbia, ¹¹Department of Rheumatology, University Medical Centre Groningen, Groningen, Netherlands, ¹²Rheumatology and clinical immunology, University Medical Center Groningen, Groningen, Netherlands, ¹³University of Birmingham, Birmingham, United Kingdom, ¹⁴Rheumatology, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹⁵Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶University of Pennsylvania, Bala Cynwyd, PA, ¹⁷Rheumatology, Konkuk University Medical Center, Seoul, South Korea, ¹⁸Konkuk University School of Medicine, Seoul, South Korea, ¹⁹Chonnam National University Medical School & Hospital, Gwangju, South Korea, ²⁰CHRU de Tours, Tours, France, ²¹Ondontology, CHU Brest, France, Brest, France, ²²CHU de Brest, Brest, France, ²³University of Brest, Brest, France, ²⁴Clinical dentistry, University of Bergen, Bergen, Norway, Bergen, Norway, ²⁵Rheumatology, Haukeland University Hospital, Bergen, Norway, ²⁶CHU Brest, Brest, France, ²⁷UBO, Brest, France
Background/Purpose: Salivary gland ultrasonography (SGUS) is commonly used in primary Sjögren Disease (pSD) as a diagnostic tool. It could also be used to monitor disease…
Abstract Number: 1636 • ACR Convergence 2023
Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren’s Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study
E. William St. Clair¹, Liangwei Wang², Ilias Alevizos², William A. Rees², Alan Baer³, Wan-Fai Ng⁴, Ghaith Noaiseh⁵ and Chiara Baldini⁶, ¹Duke University Medical Center, Durham, NC, ²Horizon Therapeutics, Rockville, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁵University of Kansas Medical Center, Kansas City, KS, ⁶University of Pisa, Pisa, Italy
Background/Purpose: Dazodalibep (DAZ) is a non-antibody fusion protein that acts as a CD40L antagonist and blocks costimulatory signals between immune cells, including T cells, B…
Abstract Number: 2188 • ACR Convergence 2023
Lung Cysts in Primary SS: New Findings on an Allegedly Innocuous Iiagnosis
Regis Sewa Marques, Maria Fernanda Zacarin, Pamela Bellini, Raissa Dudienas D Pereira, Aloma Guinami Scabora, Zoraida Sachetto, Manoel Bertolo and ALISSON PUGLIESI, Universidade Estadual de Campinas, Campinas, Brazil
Background/Purpose: Lung cysts are a frequent finding in patients with SS, with previous data indicating a prevalence of approximately 30% on chest CT scans. In…
Abstract Number: 0548 • ACR Convergence 2023
Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals
Md Yuzaiful Md Yusof¹, Sabih Ul-Hassan¹, Zoe Wigston¹, Antonios Psarras², Jack Arnold¹, Lucy Carter³, Paul Emery⁴ and Ed Vital¹, ¹University of Leeds, Leeds, United Kingdom, ²Oxford University, Oxford, United Kingdom, ³University of Leeds, Hartlepool, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Many rheumatologists find it challenging to safely discharge "At-Risk" ANA-positive people at the first visit due to lack of cardinal signs and prediction tools.…
Abstract Number: 1372 • ACR Convergence 2023
Obinutuzumab Efficacy and Tolerance in Patients with Auto-Immune Diseases Immunized Against Rituximab
Mathilde Pezot¹, Gaetane Nocturne², Rakiba Belkhir¹, Julien Henry¹, Stephan Pavy¹, Raphaele Seror³, Xavier Mariette⁴ and Samuel Bitoun⁵, ¹Rheumatology Department, Université Paris-Saclay, INSERM U1184, Hôpital Bicêtre, APHP, FHU CARE, Le Kremlin-Bicêtre, France, ²APHP, Le Kremlin-Bicêtre, France, ³University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁴Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁵CHU Bicêtre APHP, Le Kremlin-Bicêtre, France
Background/Purpose: Among patients with auto-immune diseases (AID) treated with Rituximab (RTX), anti-drug antibodies (ADAb) leading to inefficacy and infusion reactions (Wincup and al., Ann Rheum…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].